LON:TRX Tissue Regenix Group Share Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tissue Regenix Group PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 0.34 +0.01 (+3.03 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range 0.33Now: GBX 0.34▼ 0.3550-Day Range 0.30MA: GBX 0.33▼ 0.3752-Week Range 0.28Now: GBX 0.34▼ 3.50Volume7.34 million shsAverage Volume36.99 million shsMarket Capitalization£23.91 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartCompetitorsEarningsInsider TradesHeadlinesOptions Chain Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and Cardiac divisions. The company's decellularisation (dCELL) technology removes DNA and other cellular material from animal and human tissue leaving intact an inert acellular matrix upon which the patient's cells can repopulate. Its dCELL technology has applications in various clinical needs, such as wound care, and heart valve replacement. It offers DermaPure used for the treatment and management of complex and chronic wounds; and SurgiPure XD for the repair of hernias and/or body wall defects, which require the use of reinforcing or buttressing material to obtain the desired surgical outcome. The company is also developing OrthoPure XM, which makes the implant biocompatible and provides a biomechanically appropriate scaffold for cellular repopulation and eventual regeneration in the partial meniscectomy; OrthoPure XT and OrthoPure HT used for the anterior cruciate ligament injuries; and CardioPure for the replacement of human aortic and pulmonary valves. Tissue Regenix Group plc was incorporated in 2006 and is based in Leeds, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Tissue Regenix Group. Previous Next 2.7 Community Rank Outperform VotesTissue Regenix Group has received 162 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTissue Regenix Group has received 143 “underperform” votes. (Add your “underperform” vote.)Community SentimentTissue Regenix Group has received 53.11% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tissue Regenix Group and other stocks. Vote “Outperform” if you believe TRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTissue Regenix Group does not currently pay a dividend.Dividend GrowthTissue Regenix Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tissue Regenix Group insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Tissue Regenix Group is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tissue Regenix Group is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTissue Regenix Group has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.67 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:TRX Previous Symbol CUSIPN/A CIKN/A Webwww.tissueregenix.com Phone+44-1904-567609Debt Debt-to-Equity Ratio8.44 Current Ratio5.49 Quick Ratio4.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£13.05 million Price / Sales1.83 Cash FlowGBX 0.20 per share Price / Cash Flow1.68 Book ValueGBX 0.50 per share Price / Book0.68Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees100 Outstanding Shares7,032,990,208Market Cap£23.91 million Next Earnings DateN/A OptionableOptionable GBX 0.34 +0.01 (+3.03 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TRX News and Ratings via Email Sign-up to receive the latest news and ratings for TRX and its competitors with MarketBeat's FREE daily newsletter. Tissue Regenix Group (LON:TRX) Frequently Asked Questions How has Tissue Regenix Group's stock price been impacted by Coronavirus (COVID-19)? Tissue Regenix Group's stock was trading at GBX 0.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TRX shares have decreased by 58.8% and is now trading at GBX 0.34. View which stocks have been most impacted by COVID-19. How were Tissue Regenix Group's earnings last quarter? Tissue Regenix Group PLC (LON:TRX) posted its earnings results on Wednesday, September, 2nd. The company reported ($0.16) earnings per share for the quarter. View Tissue Regenix Group's earnings history. Who are some of Tissue Regenix Group's key competitors? Some companies that are related to Tissue Regenix Group include Oxford Biodynamics (OBD), Oncolytics Biotech (ONC), OncoCyte (OCX), OncoCyte (OCX), Acasti Pharma (ACST), Novoheart (NVH), 22nd Century Group (XXII), OKYO Pharma (OKYO), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), Omega Diagnostics Group (ORPH), Pediapharm (PDP), e-Therapeutics (ETX), Aerpio Pharmaceuticals (ARPO) and Sirona Biochem (SBM). View all competitors. What other stocks do shareholders of Tissue Regenix Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tissue Regenix Group investors own include Argos Therapeutics (ARGSQ), TransEnterix (TRXC), Swedbank (SWDBY), Trevena (TRVN), Allied Minds (ALM), ArQule (ARQL), CIRCOR International (CIR), WisdomTree Middle East Dividend Fund (GULF), W W Grainger (GWW) and Just Energy Group (JE). Who are Tissue Regenix Group's key executives? Tissue Regenix Group's management team includes the following people: Mr. Steven Couldwell, CEO & Director (leave of Absence) (Age 58)Mr. Gareth Hywel Jones, CFO, Company Sec. & Exec. Director (Age 50)Mr. Mike Izon, Technical DirectorCaitlin Pearson, Head of CommunicationsMr. Joel Pickering, Pres of Tissue Regenix Wound Care Inc What is Tissue Regenix Group's stock symbol? Tissue Regenix Group trades on the London Stock Exchange (LON) under the ticker symbol "TRX." How do I buy shares of Tissue Regenix Group? Shares of TRX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Tissue Regenix Group's stock price today? One share of TRX stock can currently be purchased for approximately GBX 0.34. How big of a company is Tissue Regenix Group? Tissue Regenix Group has a market capitalization of £23.91 million and generates £13.05 million in revenue each year. Tissue Regenix Group employs 100 workers across the globe. What is Tissue Regenix Group's official website? The official website for Tissue Regenix Group is www.tissueregenix.com. How can I contact Tissue Regenix Group? Tissue Regenix Group's mailing address is Innovation Way, YORK, YO10 5NY, United Kingdom. The company can be reached via phone at +44-1904-567609. This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
